Roles of Steroids in Preventing Esophageal Stricture after Endoscopic Resection

Table 2

Clinical outcomes of local steroid injection of preventing esophageal stricture after endoscopic resection.

Author, year	Design	Setting	Sample size; (treated/control)	Follow-up	Stricture rate	Mean or median number of EBD	Adverse event
Tsujii, 2017 [50]	Retrospective study	ESD>75%; SENs	28/10	Gastroscopy: a few months after ESD	43% VS 90% (P=0.012)	8 VS 5; (P>0.05)	5 VS 1
Yasuaki, 2017 [52]	Retrospective study	ESD>2/3but; <100%; SENs	37/37	Gastroscopy: every 4 weeks after ESD or receiving complaints of dysphagia	18.9% VS 45.9%; (P=0. 016)	0.6±1.5 VS; 2.8±4.6; (P<0.01)	None
Furuhashi, 2017 [53]	Historical control study	ESD≥30mm diameter or ≥3/4	43/25	Not mentioned	Multivariate analysis: OR:0.041,95%CI:0.007 to 0.24, p<0.001	2.3 VS 10.9	None
Xu, 2016 [46]	Randomized controlled trial	ESD≥1/2; SENs	17/23	Not mentioned	29.4% VS 69.6%; (P=0.02)	0.5 VS 1.3; (P=0.16)	1 VS 0
Yoshiki, 2016 [49]	Retrospective study	ESD>1/2; SENs	30/15	Not mentioned	40% VS 60%; (P>0.05)	Not significantly different	6 VS 0
Yasuaki, 2016 [47]	Retrospective study	>2/3but<3/4; ESCC	28/28	Gastroscopy: 4 and 8 weeks after the treatment.	10.7% VS 35.7%; (P=0.035)	Not mentioned	Not mentioned
Takahashi, 2015 [45]	Prospective study	ESD>75%; ESCC	16/16	Not mentioned	62.5% VS 87.5%; (P=0. 22)	6.1 VS 12.5; (P=0.04)	1.0% VS 0. 5%
Lee, 2013 [66]	Case report	ESD 100%; ESCC	1/0	Gastroscopy: 2 and 4 weeks and 4 months after ESD. Total follow-up time lasts for 6 months.	0%	0	None
Hanaoka, 2012 [44]	Prospective study	ESD>75% but<100%; ESCC	30/29	Gastroscopy: whenever patients reported dysphagia and 2 months after ESD in patients without dysphagia.	10% VS 66%; (P<0.0001)	0 VS 2; (P<0.0001)	2 VS 0
Satoru,2011 [7]	Retrospective	ESD; >75%; ESCC	21/20	Gastroscopy: assess for stenosis at 1; week, 1 month, 6 months, and 1 year after ETI.	19% VS 75%; (P<0.001)	1.7 VS 6.6; (P<0.001)	None

SENs, superficial esophageal neoplasms; LSI, local steroid injection; DSP, dexamethasone sodium phosphate; TA, triamcinolone acetonide; TTI, topical triamcinolone injection; ESCC, esophageal squamous cell carcinoma.